<span item_type="fundamental" item_id="1052df53e07d45a843cc1de381e48b87" counter_id="ST/US/BEAM" env="prod"></span><span item_type="announcement" item_id="645701359064386177" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 31.74 M, beating the estimate of USD 12.22 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.91, beating the estimate of USD -1.0166.</p><p></p><h4>Financial Performance</h4><p>Beam Therapeutics Inc. reported a net loss of - $94,318 thousand for the first quarter of 2026, which improved from a net loss of - $108,330 thousand for the first quarter of 2025. License and collaboration revenue significantly increased to $31,738 thousand for the first quarter of 2026, up from $7,470 thousand in the prior year period. Loss from operations was - $107,215 thousand for the first quarter of 2026, compared to - $119,286 thousand for the first quarter of 2025. Total operating expenses were $138,953 thousand for the first quarter of 2026, an increase from $126,756 thousand for the first quarter of 2025. Weighted-average common shares outstanding were 103,262,001 for the first quarter of 2026, an increase from 87,975,311 for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-ex99_1.htm"></span></p><h4>Operating Costs</h4><p>Research &amp; Development (R&amp;D) expenses for the first quarter of 2026 were $104,524 thousand, an increase from $98,816 thousand for the first quarter of 2025. General &amp; Administrative (G&amp;A) expenses also rose to $34,429 thousand for the first quarter of 2026, compared to $27,940 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-ex99_1.htm"></span></p><h4>Cash Position and Balance Sheet</h4><p>As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $1,211,652 thousand, a slight decrease from $1,245,210 thousand as of December 31, 2025. Total assets were $1,480,798 thousand as of March 31, 2026, compared to $1,481,177 thousand as of December 31, 2025. Total liabilities increased to $316,360 thousand as of March 31, 2026, from $242,819 thousand as of December 31, 2025. Total stockholders’ equity was $1,164,438 thousand as of March 31, 2026, down from $1,238,358 thousand as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-ex99_1.htm"></span></p><h4>Unique Operational Metrics (Pipeline Updates)</h4><p>Beam Therapeutics Inc. reported strong single-dose safety and efficacy for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD), with the 60 mg dose selected as optimal, and plans to initiate a global pivotal cohort for BEAM-302 in the second half of 2026. Data from the Phase <sup>1</sup>⁄<sub>2</sub> BEACON clinical trial of Risto-cel in Sickle Cell Disease were published, with a U.S. Biologics License Application (BLA) submission for Risto-cel expected as early as year-end 2026. An Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU) and initial clinical data from BEAM-301 in Glycogen Storage Disease type 1a (GSDIa) are anticipated in 2026, while the Phase 1 healthy volunteer clinical trial of BEAM-103 is expected to complete dosing in the first half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-ex99_1.htm"></span></p><h4>Outlook / Guidance</h4><p>Beam Therapeutics Inc. anticipates that its cash, cash equivalents, and marketable securities as of March 31, 2026, including $100 million already received and an anticipated additional $100 million from a financing agreement, will fund its operating expenses and capital expenditure requirements into mid-2029. This cash runway is expected to support the anticipated launch of Risto-cel in Sickle Cell Disease, the execution of the BEAM-302 pivotal development plan in AATD, and the achievement of clinical proof of concept for BEAM-304 in PKU.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-ex99_1.htm"></span></p>

Beam Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.74 M